"Fenofibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
| Descriptor ID |
D011345
|
| MeSH Number(s) |
D02.241.081.114.968.500.625 D02.355.726.305.625 D02.455.426.559.389.134.750 D02.455.426.559.389.657.654.305.625 D02.522.223.750
|
| Concept/Terms |
Fenofibrate- Fenofibrate
- Phenofibrate
- Procetofene
- Procetofen
Apo-Feno-Micro- Apo-Feno-Micro
- Apo Feno Micro
- Apo-Fenofibrate
- Apo Fenofibrate
Lipanthyl- Lipanthyl
- Lipantil
- Fenofibrat FPh
- Lipidil
- Secalip
- Supralip
- Fénofibrate Debat
- Debat, Fénofibrate
- Lipidil-Ter
- Lipidil Ter
|
Below are MeSH descriptors whose meaning is more general than "Fenofibrate".
Below are MeSH descriptors whose meaning is more specific than "Fenofibrate".
This graph shows the total number of publications written about "Fenofibrate" by people in this website by year, and whether "Fenofibrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 5 | 0 | 5 |
| 2012 | 10 | 0 | 10 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fenofibrate" by people in Profiles.
-
Nascent Medical Therapies for Abdominal Aneurysms. J Am Heart Assoc. 2018 10 02; 7(19):e010458.
-
An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate in Caucasians from the GOLDN cohort. J Lipid Res. 2018 04; 59(4):722-729.
-
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. J Lipid Res. 2017 04; 58(4):656-667.
-
The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats. Neuropharmacology. 2017 04; 116:364-370.
-
A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics. 2015 Oct; 25(10):511-4.
-
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
-
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
-
The peroxisomal proliferator-activated receptor (PPAR) a agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. Radiat Res. 2014 Jan; 181(1):33-44.
-
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013 Jun; 45(6):1043-50.
-
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013 Jul; 54(7):1980-7.